Top Highlights for September 2014: (Please click on read more to see details)
- Venus Remedies, India inks another pact with Mylan for marketing its Meropenem drug in 3 European countries
- Strides to acquire Shasun Pharma for $200 million
- Sun Pharma takes license for Merck's Tildrakizumab for $80 million
- Venus Remedies foray into Singapore’s topical pain management market
- Five Indian Pharma companies to sell Gilead's new Hepatitis C medicines in 90 countries Read more
- Cipla partners with S&D Pharma, UK to tap Czech Republic and Slovakia Read more
- India’s Cadila Healthcare (Zydus) eyeing US, Europe & Japan for its novel drug Lipaglyn
- Cadila Pharma scouting for partners to setup manufacturing facility in Bahrain Read more
- Indian generic drug makers eyeing Japan's $111-billion drug industry
- R&D expenditure of 25 Indian pharma cos surges by 20.6% in 2013-14 Read more
For more such news and updates on Global Life Science Business in India please join our Group on LinkedIn by the same name.
Aagami Updates: (Please click on hyperlink to view details)
- Aagami Team wishes all their Indian colleagues Happy Dussehra
- Aagami to Interact with MedTech Industry in AdvaMed 2014 (6-8 Oct) at Chicago Read more